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BACKGROUND: Our aim was to investigate the prognostic and predictive value of the oncogenic MAPKK-like protein T-cell-originated
protein kinase (TOPK) stratified by KRAS and BRAF mutations in patients with sporadic, hereditary and metastatic colorectal cancer
(CRC) treated with anti-EGFR therapy.
METHODS: Immunohistochemistry (IHC) for TOPK was performed on four study groups. Group 1 included two subgroups of 543 and
501 sporadic CRC patients used to test the reliability of TOPK expression by IHC. In Group 2, representing an additional 222 sporadic
CRCs, the prognostic effect of TOPK stratified by KRAS and BRAF was assessed. The prognostic effect of TOPK was further analysed
in Group 3, representing 71 hereditary Lynch syndrome-associated CRC patients. In Group 4, the predictive and prognostic value of
TOPK was analysed on 45 metastatic patients treated with cetuximab or panitumumab stratified by KRAS and BRAF gene status.
RESULTS: In both sporadic CRC subgroups (Group 1), associations of diffuse TOPK expression with clinicopathological features were
reproducible. Molecular analysis of sporadic CRCs in Group 2 showed that diffuse TOPK expression was associated with KRAS and
BRAF mutations (po0.001) and with poor outcome in patients with either mutation in univariate and multivariate analysis (P¼0.017).
In hereditary patients (Group 3), diffuse TOPK was linked to advanced pT stage. In metastatic patients treated with anti-EGFR therapy
(Group 4), diffuse TOPK expression was linked to dismal outcome despite objective response to treatment (P¼0.01).
CONCLUSION: TOPK expression is an unfavourable prognostic indicator in sporadic patients with KRAS or BRAF mutations and also
in patients with metastatic disease experiencing a response to anti-EGFR therapies. The inhibition of TOPK, which could benefit
30–40% of CRC patients, may represent a new avenue of investigation for targeted therapy.
British Journal of Cancer (2010) 102, 151–161. doi:10.1038/sj.bjc.6605452 www.bjcancer.com
Published online 24 November 2009
& 2010 Cancer Research UK
Keywords: colorectal cancer; TOPK; KRAS; BRAF; anti-EGFR therapy
                                                                     
The pathogenesis, progression and oncogenic behaviour of colo-
rectal cancer (CRC) are to a large extent regulated by the ERK/
MAPK signalling cascade, which activates transcription factors
critical for angiogenesis, proliferation, apoptosis, differentiation
and metastasis (Fang and Richardson, 2005). In CRC, 30–40% of
cases have mutations in the KRAS proto-oncogene (Bos et al,
1987). Often linked to tumours arising from the chromosomal
instability pathway, representing 80–85% of CRC cases, KRAS
mutations have been associated with increased activity of ERK
signalling, thereby promoting transcription of Elk-1 and c-Myc
(Bos et al, 1987; Jass, 2007). Although evidence with regard to the
effect of KRAS gene status on prognosis is heavily debated, the
majority of published studies suggest a poorer outcome in patients
with KRAS mutations (Siena et al, 2009). Interestingly, patients
with Lynch syndrome-associated CRC, representing only 2–3% of
all CRC patients, are also found to have a higher frequency of
KRAS mutation, yet they generally show a favourable clinical
outcome (Oliveira et al, 2007; Green et al, 2009). Downstream of
KRAS in ERK/MAPK signalling lies BRAF, a gene that in sporadic
disease is mutated in B10% of CRC and is more highly associated
with tumours showing microsatellite instability (MSI) (Bos et al,
1987; Jass, 2007). Few reports have investigated the prognostic
effect of BRAF in CRC; however, evidence points to a worse
prognosis in patients with mutations in this gene (Samowitz et al,
2005; French et al, 2008; Ogino et al, 2009).
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EGFR monoclonal antibodies such as cetuximab and panitumumab,
both functioning to block the binding of ligands to EGFR, thereby
downregulating ERK/MAPK and PI3K/PTEN/AKT pathway signalling
(Amado et al, 2008; Giusti et al, 2008; Segal and Saltz, 2009).
New evidence suggests that patients with KRAS, BRAF or PTEN
mutations experience fewer clinical responses to these drugs,
compared with patients with wild-type tumours; moreover, mole-
cular analysis, particularly of KRAS, is routinely being performed
in standard molecular pathology laboratories (Lievre et al, 2006;
Amado et al, 2008; Di Nicolantonio et al, 2008; Karapetis et al,
2008; Au et al, 2009; Jimeno et al, 2009; Sartore-Bianchi et al,
2009). As 30–40% of patients with CRC exhibit mutations in
one of these genes in a mutually exclusive manner, their potential
for receiving such targeted agents is substantially decreased
(Jass, 2007; Di Nicolantonio et al, 2008).
Taken together, the identification of novel prognostic and
predictive factors, which consider the heterogeneous molecular
background of CRC, particularly with regard to KRAS and BRAF
gene status, is warranted. In 2000, a new member of the ERK/
MAPK pathway, T-cell-originated protein kinase (TOPK), also
known as PDZ-binding kinase, was identified (Abe et al, 2000;
Gaudet et al, 2000). T-cell-originated protein kinase was described
as a MAPKK-like protein involved in p38MAPK and JNK
signalling, possibly in a cell-type-dependent manner, and was
more recently found to be involved in the ERK/MAPK pathway
(Matsumoto et al, 2004; Nandi et al, 2004; Ayllon and O’Connor,
2007; Oh et al, 2007). T-cell-originated protein kinase is over-
expressed in highly proliferating normal tissues, foetal tissues and
in a wide variety of tumours in vitro, whereas the inhibition of
TOPK is shown to lead to apoptosis in breast and melanoma cell
lines (Simons-Evelyn et al, 2001; Zhao et al, 2001; Matsumoto et al,
2004; Nandi et al, 2004; Dougherty et al, 2005; Park et al, 2006;
Zykova et al, 2006). Most recently, Herrero-Martin et al (2009)
evaluated TOPK expression in Ewing sarcoma cell lines and found
that the inhibition of TOPK led to a decrease in the proliferation
rate and an important change in cell growth, indicating that TOPK
could have a significant role in Ewing sarcoma biology. Zhu et al
(2007) systematically assessed this novel molecule in CRC and
confirmed its oncogenic potential in vitro and in vivo. Importantly,
they found that, unlike other MEKs that undergo negative
phosphorylation loops between themselves and ERK, TOPK could
promote malignant transformation by exerting a positive feedback
loop on ERK2 activity. However, the prognostic and predictive
effect of TOPK in patients with CRC has to date not been explored.
Given its central involvement in ERK/MAPK signalling, we hypo-
thesised that TOPK overexpression is significantly related to KRAS and
BRAF mutations, thereby implicating this gene in the poorer outcome
of patients, both in terms of prognosis and response to anti-EGFR
therapies. The aim of our study was, first, to determine using two
randomised subgroups (n¼543 and n¼501) whether TOPK expres-
sion leads to reproducible associations with clinicopathological features
by immunohistochemistry (IHC) and, second, to determine according
to KRAS and BRAF gene status the prognostic effect of TOPK on 222
sporadic and 71 Lynch syndrome-associated CRC patients, as well as
the prognostic and predictive value of TOPK in 45 metastatic CRC
patients treated with anti-EGFR agents, cetuximab and panitumumab.
METHODS
Patients
Sporadic CRC patients (Groups 1 and 2) A total of 1420 primary
pre-operatively untreated, unselected sporadic CRC patients
treated at the University Hospital of Basel between 1987 and
1996 were included in this study. Haematoxylin and eosin-stained
slides were retrospectively collected from the Institute of
Pathology, University Hospital of Basel, the Institute of Clinical
Pathology, Basel, Switzerland and from the Institute of Pathology,
Stadtspital Triemli, Zu ¨rich, Switzerland. Histopathological criteria
were reviewed by an experienced gastrointestinal pathologist (LT)
and included tumour diameter, pT and pN classification, grade of
differentiation, histological subtype, presence of vessel invasion,
tumour border configuration (pushing/expanding or infiltrating)
and presence of peritumoural lymphocytic inflammation at the
invasive tumour front (Jass et al, 1986). Clinical data including
patient age at diagnosis, tumour location and follow-up, local
recurrence, distant metastasis and post-operative therapy were
retrieved from the patient records, where available. Censored
observations included patients who were alive at the last follow-up,
those who died for reasons other than CRC or were lost to follow-
up. Median survival time was 76 (95% CI 47–137) months; median
follow-up was 60.3 months.
Lynch syndrome-associated CRC patients (Group 3) In all, 94
patients with genetically confirmed Lynch syndrome-associated
CRC identified from the Swiss Cancer Registry were included in
this study. Histopathological criteria were reviewed and included
pT, pN, pM classifications and grade of differentiation. Clinical
data including patient age at diagnosis, tumour location and
follow-up were retrieved from patient records. Censored observa-
tions included patients who were alive at last follow-up, those who
died for reasons other than CRC or were lost to follow-up. Follow-
up period ranged from 0 to 74 years and median follow-up time
was 7.1 years (95% CI 5.4–8.7).
Metastatic CRC patients (Group 4) A total of 46 consecutive
patients with histologically confirmed metastatic CRC treated
at the Oncology Institute of Southern Switzerland, Bellinzona,
Switzerland with cetuximab or panitumumab-based regimens
were entered into this study. Cetuximab was administered at
a standard loading dose of 400mgm
 2 over 2h, followed by
weekly dose of 250mgm
 2 over 1h. Panitumumab (6mgkg
 1)
was administered intravenously every 2 weeks until progres-
sion was allocated in two patients who were refractory to
oxaliplatin-based and irinotecan-based regimens. With the
exception of two patients who received cetuximab as frontline
therapy, the others had failed at least one previous chemo-
therapy regimen. For those patients who progressed on irinotecan-
based regimens, cetuximab was administered in combination
with these regimens given at the same dose and schedule.
Treatment was continued until progressive disease (PD) or
toxicity occurred, according to standard criteria. Clinical response
was assessed every 6–8 weeks with radiological examination
(computerised tomodensitometry or magnetic resonance imaging).
Figure 1 Study design. (A) 1420 sporadic colorectal cancers (CRCs) mounted onto tissue microarrays (TMA) underwent immunohistochemistry (IHC)
for TOPK and were then subdivided into Group 1 (n¼1198) and Group 2 (n¼245) on the basis of the availability of paraffin-embedded material. Excluding
154 cases, Group 1 was randomised into two matched subgroups (n¼543 and 501), then used to define ‘diffuse’ and ‘patchy’ TOPK expression and to test
associations of TOPK with cliniopathological features. In Group 2, 23 cases were excluded. A total of 222 cases with evaluable TOPK IHC were analysed for
microsatellite instability (MSI), KRAS and BRAF. The prognostic value of TOPK stratified by KRAS and BRAF gene status was determined. (B) TOPK IHC
staining was assessable in 71 of 94 Lynch syndrome-associated CRC patients in Group 3. T-cell-originated protein kinase expression was related to KRAS
and BRAF mutation, clinicopathological features and cancer-specific survival time. (C) TOPK IHC was assessable in 45 of 46 metastatic CRC patients,
whereas investigations of MSI, KRAS, BRAF and PTEN were performed. The prognostic and predictive value of TOPK in metastatic CRC patients treated
with anti-EGFR agents was evaluated.
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sThe Response Evaluation Criteria in Solid Tumours (RECIST)
were adopted for evaluation, and objective tumour response was
classified into complete response, partial response (PR), stable
disease (SD) and PD. Follow-up time ranged from 0 to 8 years,
with a median of 2.0 years and a median survival time of 2.4
(95% CI 2.0–3.4) years.
Subgroup A
(n=543)
Subgroup B
(n=501)
1420 Unselected sporadic
colorectal cancer patients
(Institute of Pathology, University Hospital Basel, Institute of
Clinical Pathology, Basel, Stadtspital Triemli, Zürich,
Switzerland)
Tissue microarray of all cases
Immunohistochemistry for TOPK
Semi-quantitative evaluation of immunostaining
GROUP 1:
Randomisation of 1044
cases into two subgroups
Exclusion of
(n=154) cases
arising from
TMA failure
Aim Group 1:
Determine cutoff score for  diffuse
and  patchy  TOPK expression and test
reproducibility of association of TOPK
with clinicopathological features
Exclusion of
(n=23) cases
arising from
TMA failure
Aim Group 2:
Determine whether TOPK expression
is linked to MSI, KRAS or BRAF gene
alterations and its impact on survival
time in sporadic colorectal cancer
Corresponding paraffin-embedded material
available (n=245)
Corresponding paraffin-embedded material
not available (n=1198)
GROUP 2:
222 cases for molecular analysis of
microsatellite instability (MSI), KRAS and BRAF
94 Genetically confirmed
patients with Lynch syndrome-
associated colorectal cancer
(Swiss Cancer Registry)
71 Cases evaluable for TOPK.
70 Paraffin-embedded
tissue blocks available for
molecular analysis of KRAS and BRAF
Aim Group 3:
Determine association of TOPK expression
with KRAS, BRAF, clinicopathological
features and survival time in hereditary
colorectal cancer
Exclusion of
(n=23) cases
arising from
TMA failure
Tissue microarray with multiple tumor
punches. Immunohistochemistry for TOPK
46 Consecutive patients with metastatic
disease treated with cetuximab or
panitumumab
(Institute of Southern Switzerland)
Average TOPK expression per case
obtained. Cases classified as  patchy  or
diffuse  using the cutoff score
determined from Group 1 subgroup A
Immunohistochemistry for TOPK
on whole tissue sections. Evaluation of TOPK as
patchy  or  diffuse  using the cutoff score
determined from Group 1
Exclusion of
(n=1) case
with insufficient
tissue for
assessment
45 Evaluable cases for TOPK and
molecular analysis of
KRAS and BRAF.
Immunohistochemistry for PTEN
Aim Group 4:
Determine the prognostic and predictive value
of TOPK expression in metastatic patients
treated by anti-EGFR agents
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For sporadic CRC patients (Groups 1 and 2), a previously
described single-punch tissue microarray was constructed
including all 1420 tumours and 57 normal mucosa samples as
control (Sauter et al, 2003; Zlobec et al, 2008). Of the 1420
tumours, paraffin-embedded surgical resection specimens were
available for 245 cases, which were retrospectively collected from
the archives of the Institute of Pathology, University Hospital
Basel, Switzerland for subsequent molecular analysis. Second, a
multiple-punch tissue microarray including all 94 patients with
Lynch syndrome-associated CRCs was constructed. Briefly, tissue
blocks were retrieved from the Research Group Human Genetics,
Department of Biomedicine, University of Basel. Haematoxylin
and eosin slides were re-evaluated and representative areas from
the tumour centre, tumour invasive front and adjacent normal
mucosa (if available) were identified using a felt-tip pen. Tissue
punches 0.6mm in diameter were taken from these areas and
brought into one recipient paraffin block (3 2.5cm) using a
homemade semi-automated tissue arrayer. The final tissue
microarray contained 297 tissues, taken from 101 different tissue
blocks, and included 135 punches from the tumour centre, 78 from
the tumour front and 84 samples of normal tissue. Third, for
patients with metastatic disease, the corresponding paraffin-
embedded tissue blocks were retrospectively collected and
whole-tissue sections were cut at 4mm.
Assay methods
Immunohistochemistry Immunohistochemistry was carried out
for all tumour specimens from Groups 1 to 4 and for normal
mucosa samples using anti-TOPK antibody. Tissue microarrays
and whole-tissue sections were dewaxed and rehydrated in dH2O.
After pressure cooker-mediated antigen retrieval in 0.001 M EDTA
(pH 8.0), endogenous peroxidase activity was blocked using 0.5%
H2O2. Sections were incubated with 10% normal goat serum for
20min. After incubation with primary antibody (PBK/TOPK,
rabbit polyclonal, dilution 1:50, Cell Signalling, Danvers, MA,
USA), sections were incubated with HRP-conjugated secondary
antibody (DakoCytomation, Glostrup, Denmark) for 30min at
room temperature, immersed in 3-amino-9-ethylcarbazole plus
substrate–chromogen (DakoCytomation) for 30min and counter-
stained with haematoxylin. Negative control tissues underwent the
same protocol with the primary antibody omitted. Tumour cell
immunoreactivity was evaluated by an experienced gastrointestinal
pathologist (AL) blinded to clinical end points. Tumour cell
staining for TOPK was predominantly observed in the cytoplasm,
rather than in the nucleus or membrane. The percentage of
positive tumour cells per case was scored. Staining intensity was
not considered. The inter-observer variability of TOPK scores was
assessed on one tissue microarray slide containing 456 cases by a
second independent pathologist (MH) from an external institution
and blinded to clinicopathological features.
Molecular analyses For groups 2, 3 and 4, MSI analysis along
with KRAS (exon 2, codons 12 and 13) and BRAF (exon 15, codon
600) mutational investigations was performed as detailed pre-
viously (Frattini et al, 2007; Lugli et al, 2009). Microsatellite stable
and MSI-low status were defined as instability at 0 and 1 markers,
respectively. Microsatellite instability-high was characterised by
the presence of instability in X2 markers (Umar et al, 2004).
Study design
The study design is outlined in Figure 1. For study groups 1–3,
excluded cases were those resulting from tissue microarray failure,
that is, insufficient tissue for evaluation or o50% tumour/punch.
Figure 2 Representative photomicrographs ( 40) after immunohistochemistry staining with anti-TOPK antibody. (A) Colorectal cancer used as a
negative control with the primary antibody omitted; (B) normal colonic mucosa with negligible cytoplasmic TOPK staining; (C) diffuse cytoplasmic TOPK
staining in 490% of colorectal tumour cells; and (D) patchy cytoplasmic staining of TOPK in p90% of colorectal tumour cells.
Prognostic and predictive value of TOPK in colorectal cancer
I Zlobec et al
154
British Journal of Cancer (2010) 102(1), 151–161 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sThe 1420 sporadic CRCs mounted onto the tissue microarray
underwent IHC for TOPK and staining was evaluated semi-
quantitatively. These cases were subdivided into two groups on the
basis of the availability of corresponding paraffin-embedded
material for subsequent DNA extraction (Figure 1A). Group 1
included cases without available tumour blocks (n¼1198),
whereas Group 2 represented cases with available archival
paraffin-embedded material (n¼245).
After exclusion of 154 cases, Group 1 was further randomised
into two matched subgroups containing 543 and 501 patients each.
The appropriate IHC cutoff score for TOPK for all study groups
was determined using subgroup A. Second, the reliability of TOPK
expression and its association with clinicopathological features
could be determined by analysing both subgroups independently.
After exclusion of 23 cases from Group 2, 222 cases underwent
molecular investigations for MSI, KRAS and BRAF. The aim of this
study group was to determine the prognostic value of TOPK in
CRCs, with subgroup analysis by KRAS and BRAF mutation.
Multivariable cancer-specific survival time models were evaluated
by including candidate variables such as age, sex, pT and pN
classification, vascular invasion and MSI status.
A total of 23 cases were excluded from Group 3 (Figure 1B).
The remaining 71 Lynch syndrome-associated CRCs underwent
molecular analysis for KRAS and BRAF. The association of TOPK
expression with mutational status of KRAS and BRAF, clinico-
pathological features and cancer-specific survival time, was assessed.
One case of metastatic CRC was excluded from Group 4
because of insufficient material for adequate assessment of TOPK
Table 1 Group 1: immunohistochemical expression of TOPK (patchy or diffuse) and association with clinicopathological features in both randomized
subgroups A and B
Subgroup A Subgroup B
Clinicopathological features Patchy N (%) Diffuse N (%) P-value Patchy N (%) Diffuse N (%) P-value
Gender
Female 211 (52.5) 75 (53.2) 0.886 200 (51.3) 62 (55.9) 0.395
Male 191 (47.5) 66 (46.8) 190 (48.7) 49 (44.1)
Tumour location
Left sided 136 (34.2) 36 (25.7) 0.008 132 (34.3) 33 (30.2) 0.027
Right sided 131 (32.9) 64 (45.7) 119 (30.9) 46 (42.2)
Rectum 131 (32.9) 40 (28.6) 134 (34.8) 30 (27.5)
Histological subtype
Mucinous 30 (7.5) 16 (11.4) 0.154 26 (6.7) 11 (9.9) 0.249
Non-mucinous 372 (92.5) 125 (88.7) 364 (93.3) 100 (90.1)
pT stage
pT1–2 77 (19.4) 23 (16.7) 0.471 67 (17.5) 18 (16.4) 0.782
pT3–4 319 (80.6) 115 (83.3) 316 (82.5) 92 (83.6)
pN stage
pN0 194 (49.6) 71 (52.2) 0.603 198 (52.4) 55 (51.9) 0.928
pN1–2 197 (50.4) 65 (47.8) 180 (47.6) 51 (48.1)
pM stage
pM0 116 (81.7) 53 (80.3) 0.812 124 (81.1) 42 (82.4) 0.836
pM1 26 (18.3) 13 (19.7) 29 (18.9) 9 (17.7)
Tumour grade
G1–2 346 (87.4) 112 (80.6) 0.04 341 (89.5) 88 (81.5) 0.025
G3 50 (12.6) 27 (19.4) 40 (10.5) 20 (18.5)
Vascular invasion
Absence 274 (69.4) 110 (79.1) 0.028 285 (74.8) 79 (72.5) 0.624
Presence 121 (30.6) 29 (20.9) 96 (25.2) 30 (27.5)
Local recurrence
Absence 73 (52.9) 43 (66.2) 0.075 90 (59.6) 30 (58.8) 0.922
Presence 65 (47.1) 22 (33.9) 61 (40.4) 21 (41.2)
Post-operative therapy
No 104 (7.3) 53 (80.3) 0.344 129 (84.9) 37 (72.6) 0.048
Yes 36 (25.7) 13 (19.7) 23 (15.1) 14 (27.5)
Mean (min, max) Mean (min, max)
Age (years) 69.9, 36–96 70.1, 39–93 0.795 70.1, 30–96 70.7, 46–96 0.654
Rate (95% CI) Rate (95% CI)
Survival time
5-year 55.7 (50–61) 62.9 (53–71) 0.337 58.6 (53–64) 54.9 (44–65) 0.843
Abbreviations: CI¼confidence interval; N¼frequency; TOPK¼T-cell-originated protein kinase.
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sexpression (Figure 1C). Immunohistochemistry for PTEN and
molecular investigations of MSI, KRAS and BRAF were previously
performed (Frattini et al, 2007). The prognostic and predictive
value of TOPK in this group of patients was analysed, with specific
end points of interest being cancer-specific survival time and
objective tumour response to anti-EGFR agents.
The use of all patient material was approved by local Ethics
Committees.
Statistical analysis methods
Associations of TOPK with categorical features were investigated
by Chi-Square and Fisher’s Exact tests where appropriate, and by
Student’s t-test for age. Survival analysis was performed using the
Kaplan–Meier method, log-rank test and by multiple Cox
regression analysis after verification of the proportional hazards
assumption. The appropriate number of variables to be included in
regression models was dependent on the frequency of patient
deaths in each analysis. We included 1 variable per 10 deaths, to
prevent overfitting. Differences in TOPK expression between
normal colonic mucosa and tumour were determined using
Wilcoxon’s rank-sum test for medians. The most clinically relevant
cutoff score for TOPK was determined on subgroup A by receiver
operating characteristic (ROC) curve analysis for end point
survival/death. To prevent overfitting, re-sampling of data was
performed by bootstrapping 200 times. The inter-observer
variability of TOPK staining was assessed using the intra-class
correlation coefficient (ICC), with values of X0.8 indicating
excellent agreement. Missing clinicopathological data were
assumed to be at random. No imputation was performed; rather,
only patients with complete data for all features were included in
multivariable analyses. P-values o0.05 were considered to be
statistically significant.
RESULTS
TOPK expression in normal colon versus sporadic CRC
T-cell-originated protein kinase expression in 57 normal colonic
mucosa samples was compared with sporadic CRCs from Group 1
(n¼1044). T-cell-originated protein kinase was highly over-
expressed in tumours with a median of 90% positive cell staining
compared with 5% positive cell staining in normal tissue
(Po0.001).
Inter-observer agreement of TOPK scoring and
determination of the cutoff score in CRC
Re-evaluation of one tissue microarray slide (n¼456 CRCs) by a
second independent pathologist from an external institution using
the same semi-quantitative scoring method resulted in ICC¼0.92,
indicating excellent agreement. Having established that the
evaluation of TOPK staining was reproducible between observers,
next, the most appropriate cutoff score to describe tumours as
overexpressed for TOPK was evaluated. Using ROC curve analysis,
the protein expression value with the highest sensitivity and
specificity for patient survival was obtained for subgroup A
(Group 1) and was found to be 90% positive for cell staining. This
value also coincided with the median expression value of TOPK in
sporadic CRCs in Group 1, hence tumours with 490% positive cell
staining for TOPK were considered ‘diffuse’, whereas cases with
p90% were defined as ‘patchy’ (Figure 2). This definition was
subsequently applied to all tumours in this study.
Group 1: TOPK in sporadic CRC and clinicopathological
information
In subgroups A and B, 141 and 111 patients had a diffuse TOPK
expression (26 and 28% of cases, respectively). In both randomised
subgroups, diffuse TOPK expression was associated with tumour
location (more right sided; P¼0.008 and P¼0.027) and with high
tumour grade (P¼0.04 and P¼0.025) (Table 1).
Table 2 Group 2: immunohistochemical expression of TOPK (patchy or
diffuse) and association with clinicopathological and molecular features in
sporadic colorectal cancer
Group 2 (N (%))
Clinicopathological features Patchy Diffuse P-value
Gender
Female 87 (54.7) 28 (44.4) 0.167
Male 72 (45.3) 35 (55.6)
Tumour location
Left sided 42 (26.4) 18 (28.6) 0.05
Right sided 47 (29.6) 27 (42.9)
Rectum 70 (44.0) 18 (28.6)
Histological subtype
Mucinous 6 (3.8) 8 (12.7) 0.027
Non-mucinous 153 (96.2) 55 (87.3)
pT stage
pT1–2 36 (22.8) 13 (21.3) 0.815
pT3–4 122 (77.2) 48 (78.7)
pN stage
pN0 84 (54.6) 36 (59.0) 0.552
pN1–2 70 (45.5) 25 (41.0)
Tumour grade
G1–2 154 (97.5) 54 (88.5) 0.012
G3 4 (2.5) 7 (11.5)
Vascular invasion
Absence 112 (70.9) 43 (70.5) 0.954
Presence 46 (29.1) 18 (29.5)
KRAS
Wild type 117 (76.5) 36 (63.2) 0.054
Mutation 36 (23.5) 21 (36.8)
BRAF
Wild type 129 (89.6) 39 (72.2) 0.002
Mutation 15 (10.4) 15 (27.8)
KRAS/BRAF
Both wild type 108 (67.9) 27 (42.9) o 0.001
KRAS or BRAF mutation 51 (32.1) 36 (57.1)
Microsatellite status
Stable/low 126 (79.3) 48 (76.2) 0.618
High 33 (20.8) 15 (23.8)
Mean (min, max)
Age (years)
Mean, range 67.6, 43–95 69.7, 44–89 0.156
Rate (95% CI)
5-year survival time
All patients 54.6 (47–63) 52.3 (39–64) 0.719
Abbreviations: CI¼confidence interval; N¼frequency; TOPK¼T-cell-originated
protein kinase.
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Figure 3 Kaplan–Meier survival curves (A) illustrating survival time differences among patients in Group 2 with KRAS or BRAF mutations stratified by
TOPK expression, (B) of metastatic colorectal cancer patients illustrating the negative effect of diffuse TOPK expression on prognosis in patients with KRAS
and BRAF wild-type tumours and (C) of patients with stable disease or response to anti-EGFR therapy. Tables describe the number of patients at risk of
death (alive) at each time point, beginning at the initial time of diagnosis when all patients are alive.
Table 3 Two multivariable analyses of TOPK expression in sporadic KRAS-mutated or BRAF-mutated colorectal cancer patients
Analysis 1 Analysis 2
Variable Hazard ratio (95% CI) P-value Variable Hazard ratio (95% CI) P-value
TOPK expression TOPK expression
Patchy 1.0 0.017 Patchy 1.0 0.018
Diffuse 2.42 (1.2–5.0) Diffuse 2.39 (1.2–4.9)
Age pT stage
Baseline year 1.0 0.004 pT1–2 1.0 0.826
1.06 (1.1–1.1) pT3–4 1.13 (0.4–3.3)
pT stage pN stage
PT1–2 1.0 0.542 pN0 1.0 0.177
PT3–4 0.71 (0.3–2.1) pN1–2 1.63 (0.8–3.3)
pN stage MSI status
pN0 1.0 0.352 MSS/MSI-L 1.0 0.112
pN1–2 1.38 (0.7–2.7) MSI-H 1.9 (0.9–4.2)
Abbreviations: CI¼confidence interval; MSI¼microsatellite instability; MSI-L¼MSI low; MSI-H¼MSI high; MSS¼microsatellite stable; TOPK¼T-cell-originated protein kinase.
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sGroup 2: TOPK in sporadic CRC, molecular features and
survival time
In Group 2, TOPK was evaluable in 222 cases. Diffuse expression,
observed in 63 patients (corresponding to 28% of cases), was
linked to tumour location (more right-sided tumours; P¼0.05),
mucinuous histological subtype (P¼0.027) and poor tumour
grade (P¼0.012) (Table 2).
Mutational investigations gave analysable sequences in 198 cases
for BRAF and 210 cases for KRAS mutations. BRAF mutations were
observed in 30 cases (15%), whereas KRAS mutations occurred in
57 cases (27%). Mutations in BRAF (P¼0.002) and KRAS (P¼0.054)
occurred more frequently in patients with diffuse TOPK staining
compared with patients with wild-type tumours. As KRAS and BRAF
mutations were mutually exclusive, the relationship of TOPK with
either KRAS or BRAF mutation was evaluated. The diffuse expression
f o u n di n3 6o f6 3( 5 7 . 1 % )p a t i e n t sw a ss i g n i f i c a n t l ya s s o c i a t e dw i t h
mutation in either KRAS or BRAF,c o m p a r e dw i t h3 2 . 1 %o fp a t i e n t s
with a patchy expression (Po0.001).
Among patients with KRAS or BRAF mutations, those with
diffuse TOPK expression had a significantly worse prognosis
compared with patients with a patchy expression (P¼0.015)
(Figure 3A). The relative risk of death for patients with KRAS or
BRAF mutations was 2.22 (95% CI 1.1–4.4) compared with those
showing no mutation in either gene. In multivariate survival
Table 4 Group 3: immunohistochemical expression of TOPK (patchy or
diffuse) and association with clinicopathological and molecular features in
hereditary Lynch syndrome-associated colorectal cancers
Group 3 (N (%))
Clinicopathological features Patchy Diffuse P-value
Gender
Female 22 (53.7) 18 (60.0) 0.635
Male 19 (46.3) 12 (40.0)
Tumour location
Left sided 18 (46.2) 11 (39.3) 0.21
Right sided 12 (30.7) 14 (50.0)
Rectum 9 (23.1) 3 (10.7)
pT stage
pT1–2 12 (31.6) 2 (6.9) 0.014
pT3–4 26 (68.4) 27 (93.1)
pN stage
pN0 23 (65.7) 14 (51.9) 0.27
pN1–2 12 (34.3) 13 (48.2)
pM stage
pM0 14 (70.0) 5 (55.6) 0.675
pM1 6 (30.0) 4 (44.4)
Tumour grade
G1–2 24 (72.7) 18 (64.3) 0.478
G3 9 (27.3) 10 (35.7)
KRAS
Wild type 28 (68.3) 20 (61.0) 1.0
Mutation 13 (31.7) 9 (31.0)
BRAF
Wild type 38 (100.0) 28 (96.6) 0.433
Mutation 0 (0.0) 1 (3.5)
KRAS/BRAF
Both wild type 28 (68.3) 19 (65.5) 1.0
KRAS or BRAF mutation 13 (31.7) 10 (34.5)
Microsatellite status
Stable/low
High 41 (57.3) 30 (42.3) 0.192
Mean (min, max)
Age (years)
Mean, range 45.3, 24–73 47.4, 27–83 0.492
Rate (95% CI)
5-year survival time
All patients 87.5 (73–95) 88.7 (69–96) 0.66
Abbreviations: CI¼confidence interval; EGFR¼epidermal growth factor receptor;
N¼frequency; TOPK¼T-cell-originated protein kinase.
Table 5 Group 4: Immunohistochemical expression of TOPK (patchy or
diffuse) and clinicopathological and molecular features in metastatic
colorectal cancer patients treated with anti-EGFR therapy
N (%)
Clinicopathological features Patchy Diffuse P-value
Age (years)
Mean, range 65.7, 48–82 60.7, 26–79 0.113
Gender
Female 8 (36.4) 9 (39.1) 0.848
Male 14 (63.6) 14 (60.9)
Clinical response
Progressive disease 13 (59.1) 10 (43.5) 0.528
Partial response 4 (18.2) 7 (30.4)
Stable disease 5 (22.7) 6 (26.1)
KRAS codon 12 and 13
Wild type 13 (59.1) 19 (82.6) 0.082
Mutation 9 (40.9) 4 (17.4)
BRAF codon 600
Wild type 20 (90.9) 21 (91.3) 1.0
Mutation 2 (9.1) 2 (8.7)
KRAS/BRAF
Both wild type 11 (50.0) 17 (73.9) 0.098
KRAS or BRAF mutation 11 (50.0) 6 (26.1)
Microsatellite status
Stable/low 22 (100.0) 22 (100.0)
High
EGFR amplification
No copy number gain 4 (19.1) 3 (13.0) 0.693
Copy number gain 17 (81.0) 20 (87.0)
PI3KCA
Loss 19 (86.4) 20 (87.0) 1.0
Overexpression 3 (13.6) 3 (13.0)
PTEN
Loss 11 (50.0) 6 (26.1) 0.09
Overexpression 11 (50.0) 17 (73.9)
Rate (95% CI)
5-year survival time
All patients 34.5 (11–60) 13.5 (1–40) 0.473
Either KRAS or BRAF mutation 18.2 (3–44) 16.7 (0–51) 0.887
Both wild type KRAS and BRAF 66.7 (5–95) 15.3 (1–45) 0.018
Stable disease or response 100 31.3 (8–59) 0.01
Abbreviations: CI¼confidence interval; EGFR¼epidermal growth factor receptor;
N¼frequency; TOPK¼T-cell-originated protein kinase.
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expression maintained a significant adverse effect on outcome
(P¼0.017; HR¼2.42 (95% CI 1.2–5.0)), as well as after adjusting
for the prognostic effects of pT classification, pN classification and
MSI status (P¼0.018; HR¼2.39 (95% CI 1.2–4.9)) (Table 3).
Group 3: TOPK in hereditary Lynch syndrome-associated
CRC
T-cell-originated protein kinase expression could be assessed in
71 patients with Lynch syndrome-associated CRC. Of the 30
patients with a diffuse TOPK expression (41% of cases), 27 (93.1%)
had pT3 or pT4 tumours compared with 68.2% of patients with a
patchy expression (P¼0.014). KRAS mutations were found in 22
(31%) patients, whereas mutation in BRAF was noted in only one
case of genetically confirmed Lynch syndrome. No association of
TOPK was observed with either prognosis or KRAS mutation
status (Table 4).
Group 4: TOPK in metastatic CRC patients treated with
anti-EGFR therapy
Of the 45 metastatic patients treated with cetuximab or
panitumumab with evaluable TOPK staining, a wild-type KRAS
and BRAF gene status was detected in 32 (71.1%) and 41 (91%)
cases, respectively. Diffuse TOPK expression was observed in 19
(82.6%) KRAS wild-type and 21 (91.3%) BRAF wild-type tumours.
A highly unfavourable outcome in patients with KRAS and BRAF
wild-type tumours with overexpression of TOPK was noted
(P¼0.018) (Figure 3B). No difference in TOPK staining was found
between PTEN loss and overexpression, and the prognostic effect
of diffuse TOPK staining in KRAS and BRAF wild-type patients
was maintained after adjusting for PTEN status (P¼0.041). In
total, 23 patients (51.1%) had PD, 11 (24.4%) had PR and 11
(24.4%) had SD, with diffuse expression of TOPK occurring in 10
(43.5%), 7 (30.4%) and 6 (26.1%) patients, respectively. Patients
having SD or PR to anti-EGFR therapy but with diffuse TOPK
expression suffered from poor outcome; in contrast, those with no
overexpression of TOPK were alive or censored at 5-year follow-up
(P¼0.01) (Figure 3C). T-cell-originated protein kinase expression
was not of predictive value for response to anti-EGFR therapy,
either in the entire cohort of patients or when stratified by KRAS
and BRAF mutation status (Table 5).
DISCUSSION
We report the association of diffuse TOPK expression with
specific sporadic CRC features, namely, with right-sided
tumour location and higher tumour grade in two large multicentric
cohorts of patients and excellent inter-observer reproducibility
of TOPK scores. Second, our findings point to the diffuse
expression of TOPK as an adverse prognostic factor in patients
with sporadic CRC with a KRAS or BRAF mutation and in
metastatic patients with SD or PR after treatment with anti-EGFR-
based regimens.
In sporadic CRC, diffuse TOPK expression was associated with
the presence of KRAS or BRAF mutation, underlining the
involvement of TOPK in ERK/MAPK signalling. In patients with
either KRAS or BRAF mutations, diffuse expression of TOPK had
an adverse effect on 5-year survival. In addition, this unfavourable
effect of TOPK expression on outcome was maintained in
multivariate analysis, suggesting that TOPK could represent an
important prognostic factor in patients with KRAS-mutated or
BRAF-mutated tumours (Andreyev et al, 1998; Samowitz et al,
2005; French et al, 2008; Ogino et al, 2009). Although KRAS
mutations are frequently found in patients with Lynch syndrome-
associated CRC despite their favourable prognosis, in this study,
no association between TOPK expression and KRAS mutation
was observed (Oliveira et al, 2007). The propensity for more
right-sided, poorly differentiated cancers and poorer outcome in
patients with KRAS or BRAF mutation was not found here, despite
an association with a more advanced pT stage with diffuse TOPK
staining. These results seem to indicate that involvement of TOPK
in CRC may be limited to tumours of sporadic origin.
We report that in 45 metastatic CRC patients treated with anti-
EGFR agents and with wild-type KRAS and BRAF gene status,
those expressing diffuse TOPK staining suffer from a significant
adverse prognosis. In addition, TOPK expression seemed to be
unmodified by PTEN status and maintained its adverse effect on
outcome in KRAS or BRAF wild-type patients independently of the
expression of this molecule. Furthermore, among patients with SD
or those with objective response, a diffuse expression of TOPK
may act as a highly unfavourable prognostic factor. Together, these
results indicate that the activation of MAPK signalling is still
possible at the level of TOPK, even in the context of wild-type
KRAS and BRAF, and is unlikely because of loss of PTEN.
Therefore, TOPK may act as a prognostic, rather than as a
predictive, factor, suggesting that it may be important to consider
its expression in metastatic CRC patients with a proficient
molecular profile for positive response to anti-EGFR drugs.
Our results suggest that inhibition of TOPK could be beneficial
for at least two groups of CRC patients together representing 30–
40% of all cases, namely, those with a KRAS or BRAF mutation and
those with metastatic disease supported by several factors. T-cell-
originated protein kinase is barely detectable in most normal adult
tissues including normal colonic mucosa, whereas it is highly
overexpressed in CRC (Zhu et al, 2007). Its detection by IHC leads
to reproducible associations with clinicopathological features and
its evaluation leads to excellent inter-observer agreement. As a
MAPKK-like protein, it is a downstream molecule of KRAS and
BRAF, both of which are associated with diffuse expression of
TOPK (Roberts and Der, 2007). T-cell-originated protein kinase
may itself be an effector of BRAF, as phosphorylation of TOPK by
RAF has previously been shown (Yuryev and Wennogle, 2003).
Therefore, inhibition of TOPK at this level of signalling may have a
more significant impact on downregulating deregulated ERK/
MAPK signalling. Current MEK inhibitors have led to moderate
results (Roberts and Der, 2007). Although blocking MEK1 should
lead to a decrease in the phosphorylation of ERK1/2, this process is
hindered by a negative feedback loop of ERK1/2 onto MEK1,
making inhibition of this molecule to some extent counter
productive (Ramos, 2008). T-cell-originated protein kinase, in
contrast, has been described as an oncogenic MEK involved in a
positive phosphorylation loop with ERK2 (Zhu et al, 2007).
Therefore, inhibition of TOPK should be expected to successfully
decrease the activation of ERK2 and thus its downstream
transcription factors. Moreover, TOPK expression in this study
seems to be independent of PTEN status. Considering recent
evidence suggesting that PTEN mutation results in resistance to
EGFR-targeted therapies (Sartore-Bianchi et al, 2009), the inhibi-
tion of TOPK in KRAS and BRAF wild-type patients could
represent an approach to improve clinical outcome in patients
with either PTEN wild-type or mutated cancers.
A limitation of this study is that information on cancer
treatment was limited. Subgroup analysis produced results using
relatively small sample sizes; therefore, these findings necessitate
validation on larger patient cohorts. Nonetheless, our study gives
valuable results for several reasons. Four groups of patients were
included, representing sporadic, hereditary and metastatic CRC.
Patients were treated in different centres and considerable
corresponding clinicopathological data and follow-up could be
obtained. Whole-tissue sections and two tissue microarrays were
evaluated, the largest containing more than 1000 tumours, the
second with multiple tissue punches taken from the same patient
representing different tumour areas. Finally, the cohort of
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smetastatic CRC was well characterised with respect to both
clinicopathological treatment and molecular features.
Although several study groups have investigated the functional
role of TOPK in different tumour types, this seems to be the first
assessment of the prognostic and predictive value of this protein in
CRC. In conclusion, TOPK seems to be a valuable prognostic factor
in patients with sporadic CRC with KRAS or BRAF gene mutations,
as well as in patients with metastatic disease who respond to anti-
EGFR therapies. If confirmed prospectively, the inhibition of
TOPK may represent a novel avenue of investigation for targeted
treatment in patients with CRC, especially for the early identifica-
tion of patients with a worse prognosis, although experiencing
disease control after anti-EGFR drug administration.
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